New hypertension threshold linked to 73% higher risk for vascular events in lupus

A 2-year, sustained mean blood pressure of 130-139/80-89 mm Hg — now considered the threshold for stage 1 hypertension by the American College of Cardiology and the American Heart Association — is associated with a 73% higher risk for atherosclerotic vascular events among patients with lupus, according to data published in the Annals of the Rheumatic Diseases.

“The recently published guidelines for the management of arterial hypertension in adults by the American College of Cardiology/American Heart Association (ACC/AHA) recommended a significantly lower threshold of systolic and diastolic blood pressure (SBP, DBP) for diagnosis,” Konstantinos Tselios, MD, PhD, of the University of Toronto Lupus Clinic, and colleagues wrote. “The levels of 130-139mm Hg for SBP and 80-89mm Hg for DBP are now considered as stage 1 hypertension, in contrast to the previous recommendations in which hypertension was defined as BP 140/90mm Hg.”

Few AIM-listed drug development companies have late-stage clinical assets in the pipeline, ImmuPharma plc (LON:IMM) is an exception. The Company’s lead compound, Lupuzor™, a potential treatment for Lupus, has completed Phase 3 trial of dosing patients across the US, Europe and Mauritius with top line results announced.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Facebook
    Share on twitter
    Twitter
    Share on linkedin
    LinkedIn
    Immupharma Plc

    More articles like this

    Immupharma Plc

    Learning About Lupus

    May is Lupus Awareness Month. It is a disease that is relatively common in the Caribbean yet many of us are unfamiliar with the condition. Lupus is an autoimmune condition that can affect almost every system in the

    Immupharma Plc

    ImmuPharma Change of Registered Office Address

    ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today announced that with immediate effect, its registered office address has been changed to: One Bartholomew Close, London, EC1A 7BL.

    Immupharma Plc

    ImmuPharma Change of AGM Venue

    ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, today announced that the Company’s Annual General Meeting confirmed for Thursday, 18 June 2020 @ 10.30am, will now be held at: 52 Grosvenor Garden, London SW1W 0AU. The COVID-19 Guidance rules

    Immupharma Plc

    Lupus Latest Facts: Causes, Symptoms and Treatments

    Lupus is a relatively rare inflammatory disease. In the US 1.5 million are currently living with the condition. It is an autoimmune disease that can affect various organs including the skin, joints, kidneys, and brain. What are the

    Immupharma Plc

    Selena Gomez urges fans to join the fight against Lupus

    US singer Selena Gomez has urged her fans across the world to join the fight against Lupus, an autoimmune disease. The disease leads to the body’s immune system becoming hyperactive, attacking normal and healthy tissues. On World Lupus

    Immupharma Plc

    Understanding Lupus

    Lupus is a chronic (long-term) disease that can cause inflammation and pain in any part of your body. It’s an autoimmune disease, which means that your immune system — the body system that usually fights infections — attacks

    Immupharma Plc

    What to know about COVID-19 and lupus

    Lupus is a chronic autoimmune condition in which the immune system attacks its own tissues. People with lupus are at higher risk of infections, and those with lupus who develop COVID-19 may be at higher risk of developing

    Immupharma Plc

    Frequently asked questions: coronavirus (COVID-19) and lupus

    Our Health Educator Network—health-care professionals and lupus specialists who provide individualized answers—have seen their inquires triple in the last week. The following are questions they’ve been frequently asked and their answers. Should I wear a facemask? The CDC recommends that

    Immupharma Plc

    Are People with Lupus Protected Against COVID-19?

    There is no evidence that taking hydroxychloroquine (Plaquenil) is effective in preventing a person from contracting the coronavirus (COVID-19). People with lupus should follow the guidance of their doctor and the safety guidelines being issued by the CDC.

    Immupharma Plc

    Dr Miriam Stoppard on Lupus

    Lupus isn’t that common but when it strikes it can be very ­serious, even life-threatening. The story of the singer and ­actress Selena Gomez is a case in point. All lupus sufferers will be grateful to her because she’s increased

    No more posts to show